|
|
FDA Approves Remicade® for Psoriatic Arthritis
May 18, 2005, 08:40, Reviewed by: Dr.
|
|
"The approval of REMICADE for psoriatic arthritis means that my patients now will have a new option for treatment for this potentially crippling disorder and will have approved access to these treatments."
|
By Centocor, Inc.,
THE U.S. FOOD AND DRUG ADMINISTRATION RECENTLY APPROVED REMICADE® FOR REDUCING THE SIGNS AND SYMPTOMS OF ACTIVE ARTHRITIS IN PATIENTS WITH PSORIATIC ARTHRITIS.
NEARLY 30 PERCENT OF THE MORE THAN FOUR MILLION PEOPLE WITH PSORIASIS MAY DEVELOP PSORIATIC ARTHRITIS, WHICH CAN RESULT IN SWOLLEN, PAINFUL JOINTS AND SCALY, INFLAMED SKIN.
MOST PEOPLE WHO DEVELOP PSORIATIC ARTHRITIS BEGIN TO EXPERIENCE ARTHRITIS SYMPTOMS APPROXIMATELY 10 YEARS AFTER SKIN SYMPTOMS APPEAR. PSORIATIC ARTHRITIS CAN BE DIFFICULT TO DIAGNOSE, BUT EARLY DIAGNOSIS AND PROPER TREATMENT ARE KEY FOR PREVENTING LONG-TERM DAMAGE TO JOINTS AND TISSUE.
DOCTOR ALICE GOTTLIEB, DIRECTOR OF THE CLINICAL RESEARCH CENTER AT THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY-ROBERT WOOD JOHNSON MEDICAL SCHOOL:
"The approval of REMICADE for psoriatic arthritis means that my patients now will have a new option for treatment for this potentially crippling disorder and will have approved access to these treatments." 
- U.S. Food and Drug Administration (FDA)
www.psoriasis.org
Privided by DANIELLE ADDAIR.
FOR MORE INFORMATION ON PSORIATIC ARTHRITIS VISIT PSORIASIS.ORG.
For full prescribing information visit, http://www.remicade.com
ADDITIONAL RESOURCES: Audio version and more available at http://www.prnewswire.com/broadcast/21228/consumer.shtml
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
|
|
|
